© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Laurence Klotz, MD, FRCSC, CM
Articles
Active Surveillance for Prostate Cancer: How to Do It Right
May 15, 2017
In this review of active surveillance for favorable-risk prostate cancer, we will discuss the rationality of this approach, the biological evidence for employing active surveillance in Gleason pattern 3 and 4 prostate cancer, patient selection for active surveillance, clinical trial data on active surveillance, and the role of prostate cancer biomarkers and imaging studies for clinical decision making in patients with low-risk disease.
Laurence Klotz on the Controversy Surrounding Screening for Prostate Cancer
August 15, 2016
In this interview we discuss PSA screening for prostate cancer, the compromised results of the PLCO trial, and more.
Low-Risk and Very-Low-Risk Prostate Cancer: Is There a Role for Focal Therapy in the Era of Active Surveillance? Yes, the Two Approaches Complement Each Other
November 15, 2014
Investigators and physicians caring for the spectrum of prostate cancer should have a targeted treatment option available for patients who would benefit by it.
Active Surveillance Not Only Reduces Morbidity, It Saves Lives
June 15, 2013
The concept of active surveillance is based on the observation that Gleason 6 (pattern 3) prostate cancer is an indolent condition that poses little or no threat to the patient’s life. Conservative management is thus appropriate for these patients.